You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 28, 2025

Drug Price Trends for NARDIL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for NARDIL

Market Analysis and Price Projections for Nardil (Phenelzine)

Introduction to Nardil

Nardil, also known as phenelzine sulfate, is a monoamine oxidase inhibitor (MAOI) used primarily for the treatment of depression, particularly in cases where other antidepressants have proven ineffective. It is often prescribed for patients with atypical, nonendogenous, or neurotic depression.

Market Demand and Shortages

The demand for Nardil has been significant, especially given its role as a last-resort treatment for depression. However, the market has been impacted by a global shortage of the active ingredient, phenelzine. This shortage, which began in March 2020, has been particularly challenging for Canadian patients, with Health Canada estimating that the shortage would last until April 2021[1][4].

Impact on Patients

The shortage has had severe consequences for patients who rely on Nardil. Many have reported increased risk of self-harm, suicidal ideation, and significant disruptions to their daily lives due to the lack of this critical medication[4].

Market Size and Growth

The global antidepressants market, within which Nardil operates, is projected to grow significantly. By 2027, the market is expected to reach USD 18.29 billion, driven by a CAGR of 2.9% during the forecast period. The COVID-19 pandemic has accelerated this growth due to increased prevalence of depression and anxiety[3].

Regional Market Dynamics

North America is expected to dominate the antidepressants market, largely due to the strong presence of major pharmaceutical companies like Pfizer and Merck. Europe and Asia Pacific are also expected to see significant growth, driven by investments in clinical trials and increasing incidence of mental health disorders[3].

Pricing and Cost Considerations

Current Pricing

The cost of Nardil can vary depending on the pharmacy and the availability of discounts. For a supply of 60 tablets of Nardil 15 mg, the cost is approximately $171. However, generic versions of phenelzine are available at a lower cost, around $44.57 for 60 tablets[2][5].

Price Projections

Given the ongoing shortages and the critical nature of Nardil, prices may fluctuate. Here are some key points to consider:

  • Short-term Volatility: During periods of shortage, prices may increase due to supply and demand imbalances. Patients may face higher costs or difficulties in accessing the medication.
  • Long-term Stability: Once the shortage is resolved, prices are likely to stabilize. However, the overall trend in the antidepressants market suggests that prices may remain relatively high due to the specialized nature of the drug and its critical role in treating specific types of depression.
  • Generic Options: The availability of generic phenelzine can help mitigate price increases. Generic versions are significantly cheaper and can provide a more affordable alternative for patients[2][5].

Alternative Treatments and Mitigation Strategies

Alternative Medications

Health Canada and the manufacturer, ERFA, have recommended not starting new patients on Nardil and safely switching existing patients to alternative treatments. However, experts like Mina Tadrous from the University of Toronto emphasize that Nardil does not have a comparable alternative, making these transitions challenging[4].

Foreign Supply and Regulatory Approvals

Efforts to explore access to foreign supply have been ongoing, but any alternative phenelzine must be regulated and approved by Health Canada to ensure safety and efficacy[4].

Key Takeaways

  • Critical Demand: Nardil is a crucial medication for patients with specific types of depression, and its shortage has significant health implications.
  • Market Growth: The global antidepressants market is growing, driven by increased awareness and prevalence of mental health conditions.
  • Pricing Volatility: Prices for Nardil may fluctuate due to shortages, but generic options can provide some stability.
  • Alternative Strategies: Health authorities are working to mitigate the impact of the shortage by exploring alternative treatments and foreign supply options.

FAQs

What is Nardil used for?

Nardil, or phenelzine sulfate, is used to treat certain types of depression, particularly those that are atypical, nonendogenous, or neurotic.

Why is there a shortage of Nardil?

The shortage is due to a global shortage of the active ingredient, phenelzine, which has affected the Canadian manufacturer's ability to supply the medication consistently.

How long is the Nardil shortage expected to last?

The shortage was initially expected to last until April 2021, but updates may have changed this timeline.

Are there alternative medications to Nardil?

While there are other antidepressants, Nardil does not have a directly comparable alternative, making transitions to other medications challenging for some patients.

How can patients mitigate the cost of Nardil?

Patients can use discount cards, copay cards, and consider generic versions of phenelzine to reduce costs.

Sources

  1. Global News: "Shortage of last-resort antidepressant creating 'scary situation' for Canadian patients"[1]
  2. Drugs.com: "Nardil Prices, Coupons, Copay Cards & Patient Assistance"[2]
  3. GlobeNewswire: "Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™"[3]
  4. CTV News: "Nardil shortage has some Canadians turning to thoughts of self-harm"[4]
  5. Drugs.com: "Phenelzine Prices, Coupons, Copay Cards & Patient Assistance"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.